Interdisciplinary symposium bringing together basic science and clinical applications
Up-to-date research findings at the highest scientific level
This book, the proceedings of Falk Symposium 163 “Chronic Inflammation of Liver and Gut”, held in Hangzhou, P.R. China, on March 14--15, 2008, presents the most recent progress in chronic inflammatory diseases of liver and gut. It focusses on molecular understanding, the therapeutic state of the art and future options of treatment. The first part of the book concentrates on basic and clinical aspects of IBD. Chapters demonstrate the role of the immune system, genetic factors and the intestinal microflora in IBD, and give an evidence-based update on the current diagnostic and therapeutic options and present future perspectives for the management of IBD. The second part is devoted to chronic liver diseases with particular focus on the liver as an immune organ, treatment strategies of viral hepatitis and liver fibrogenesis. The final part deals with basic and clinical aspects of liver cirrhosis, hepatocellular carcinoma and liver transplantation. The book concludes with an outlook on therapeutic options of hepatic stem cells. Throughout, international experts from the USA, the People’s Republic of China and Europe contribute their experience in different aspects of the mechanisms and management of chronic inflammatory diseases of liver and gut.
List of principal contributors List of chairpersons Preface INFLAMMATORY BOWEL DISEASE (SESSION I).- 1 State-of-the-Art Lecture: Pathogenesis of inflammatory bowel disease: converging paradigms.- 2 The role of the epithelium in inflammatory bowel disease.- 3 Implications of genetics for clinical practice.- 4 Epidemiology of inflammatory bowel disease in China.- 5 State-of-the-Art Lecture: The enteric microbiota: implications in inflammatory bowel disease.- 6 Can we predict the natural history of ulcerative colitis?.- INFLAMMATORY BOWEL DISEASE (SESSION II).- 7 Practical use of steroids in inflammatory bowel disease.- 8 Prevention of cancer in inflammatory bowel disease and the potential chemopreventive effect of aminosalicylates.- 9 Therapy of inflammatory bowel disease: bottom-up or top-down?.- 10 State-of-the-Art Lecture: The future of biologic therapy in Asia.- CHRONIC LIVER DISEASE (SESSION I).- 11 State-of-the-Art Lecture: The liver as an immune organ.- 12 Treatment strategies for hepatitis B in the West.- 13 Treatment strategies of hepatitis B in China.- 14 State-of-the-Art Lecture: The treatment of hepatitis C.- 15 State-of-the-Art Lecture: Non-alcoholic steatohepatitis: concepts on pathogenesis and therapy.- 16 Liver fibrogenesis: how to stop progression?.- 17 Clinical aspects of primary biliary cirrhosis.- CHRONIC LIVER DISEASE (SESSION II).- 18 Pathophysiology of portal hypertension and variceal bleeding.- 19 Management of ascites and hepatorenal syndrome.- 20 Antiviral therapy for hepatitis B virus-associated hepatic failure.- 21 Adult-to-adult living donor liver transplantation -- triumphs and challenges.- 22 Chronic infection of hepatitis B virus and hepatocellular carcinoma in China.- Index